Follow us

Pipeline

Proof of concept to be generated by 8 clinical trials

Indications

Protocol

Location

Preclinical

Clinical Stage

Phase 1

Phase 2

Phase 3

Brain Metastases

brain

NANORAD 2
CHU Grenoble-Alpes

100 patients randomized

Europe
Recruiting Phase 2
flèche verte

NANOBRAINMETS
Dr. Aizer at Dana-Farber/Harvard Cancer Center
134 patients randomized

USA
Recruiting Phase 2
flèche verte

Cervical Cancer

Cervical cancer

NANOCOL
Institut Gustave Roussy
12 patients

Europe
Recruiting Phase 1
flèche verte
ODD

Pancreatic/
Lung Cancer

Pancreatic / Lung Cancer

NANOSMART
Dr. Leeman at Dana-Farber/Harvard Cancer Center
100 patients randomized

USA
Recruiting Phase 1
flèche verte
ODD

Glioblastoma

brain

NANO-GBM
Centre Jean Perrin
66 patients randomized

Europe
Recruiting Phase 1
flèche verte

Other Indications

(Rectal, Head & Neck, Musculoskeletal tumor)

NANOREC
Leeds University
34 patients

United Kingdom
Phase 1/2 protocol in preparation


NANOPRO
Centre François Baclesse

46 patients

Europe
Phase 2 protocol approuved

NANORT-MSK
Centre Léon Bérard
132 patients randomized

Europe
Phase 2 protocol approuved

ODD: Orphan Drug Designation obtained from both the FDA and the EMA